Use of compounded L-asparaginase became routine in veterinary oncology when manufacturing of Elspar® was discontinued in 2012. The objective of this study was to evaluate the safety of compounded L-asparaginase (CLASP, KRS Global Biotechnology, Boca Raton, FL, USA) in comparison with Elspar® (Lundbeck LLC, Deerfield, IL, USA). In addition, we documented the response to CLASP in combination with...

The pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant Escherichia coli–asparaginase preparation was compared with Asparaginase medac. Thirty-two children with acute lymphoblastic leukemia were randomized to receive one of both agents at a dose of 5000 U/m2 every 3 days, for a total of 8 doses during induction treatment. The serum activity-time profile after the first...

The acute effects of a single intravenous dose of L-asparaginase on protein synthesis were studied in normal rabbits and in animals that had received turpentine to stimulate fibrinogen production. Male New Zealand rabbits received L-asparaginase (500 U/kg) 16 hr before the injection of the radiolabeled amino acid [75Se]selenomethionine (75SeM). Incorporation of 75SeM into fibrinogen and serum p...

Endophytes are novel sources of natural bioactive compounds. This study seeks endophytes that produce the anticancer enzyme l-asparaginase, to harness their potential for mass production. Four plants with anticancer properties; Cymbopogon citratus, Murraya koenigii, Oldenlandia diffusa and Pereskia bleo, were selected as host plants. l-Asparaginase-producing endophytes were detected by the form...

BACKGROUND Chemotherapy with L-asparaginase is associated with hepatotoxicity resulting in organ dysfunction in patients with preexisting liver disorders. This study investigated the protective effect of L-carnitine during chemotherapy in a steatotic rat liver model. METHODS Livers from nonsteatotic and steatotic rats were tested in an isolated liver reperfusion model adding L-asparaginase an...

Of 15 L-asparaginase preparations tested, 13 inhibited whole human serum complement; the inhibitory effect ranged from 12 to 45%. We have partially characterized the anticomplementary activity in one of the L-asparaginase preparations. The anticomplementary activity was separable from the L-asparaginase activity on Sephadex G-200. Fractions containing L-asparaginase had no effect either on whol...

Three hundred and sixty four (364) isolates of tropical soil fungi were screened for L-asparaginase production by rapid plate method using modified Czapek-Dox agar containing L-asparagine, and either bromo cresol purple or phenol red dye as an indicator. Results of the study revealed that total one hundred and thirty five (135) isolates showed positive reaction for L-asparaginase production as ...

L-Asparaginase was used to treat 40 patients with acute leukaemia or lymphosarcoma. Fifteen with acute lymphoblastic leukaemia either untreated or in relapse after previous therapy were given "Squibb," "Bayer," or "Porton" L-asparaginase. Five of these patients had complete remission of their disease, and four had good partial remission. Eleven patients with acute myeloid leukaemia were treated...

L-asparaginase is a hydrolase that catalyzes the conversion of L-asparagine--an endogenous amino acid necessary for the function of some neoplastic cells, such as lymphoblasts. In most human cells deficiency of L-asparagine can be compensated by alternative synthesis pathway through which L-asparagine is produced from aspartic acid and glutamine by asparagine synthethase. Depletion of L-asparag...

Asparaginases are known to be the cornerstone for treatment of acute lymphoblastic leukemia (ALL) and are used for treatment in all pediatric regimens as well as in the majority of adult treatment protocols. Clinical hypersensitivity reactions against commercially available asparaginase have resulted in failure of asparaginase in treatment of ALL in more than 60% of cases. Thus, it is required ...